Compositions and methods for nanoparticle lyophile forms

Patent metadata

Field	Value
Publication number	US-10300018-B2
Application number	US-201615217098-A
Country	US
Kind code	B2
Filing date	Jul 22, 2016
Priority date	Jul 22, 2015
Publication date	May 28, 2019
Grant date	May 28, 2019

Abstract

This invention provides compositions for making a solid lyophile of one or more nucleic acid active agents, which can be reconstituted as a drug product. The composition can include an aqueous suspension of lipid nanoparticles in a pharmaceutically acceptable solution, wherein the lipid nanoparticles encapsulate one or more nucleic acid active agents, a dextrin compound, and a saccharide compound. The nucleic acid active agents can be RNAi molecules capable of mediating RNA interference, as well as other RNAs and oligonucleotides.

First claim

What is claimed is:

1. A composition for making a solid lyophile of lipid nanoparticles comprising one or more nucleic acid active agents, the composition comprising:
an aqueous suspension of the lipid nanoparticles in a pharmaceutically acceptable solution, wherein the lipid nanoparticles encapsulate the one or more nucleic acid active agents;
a dextrin compound;
a saccharide sugar compound;
wherein the total amount of the dextrin and sugar compounds is from 2% to 20% (w/v) of the composition;
wherein the dextrin compound is from 40% to 70% (w/v) of the total amount of the dextrin and sugar compounds; and
wherein upon lyophilization and reconstitution of the composition without filtering, the average size of the nanoparticles is within 5% of their size in the original composition with PDI less than or equal to 0.15.

2. The composition of claim 1 , wherein the dextrin compound is from 40% to 55% (w/v) of the total amount of the dextrin and sugar compounds.

3. The composition of claim 1 , wherein the dextrin compound is 40% to 45% (w/v) of the total amount of the dextrin and sugar compounds.

4. The composition of claim 1 , wherein upon lyophilization, storage and reconstitution of the composition, the average size of the nanoparticles is within 10% of their size in the original composition.

5. The composition of claim 4 , wherein the lyophilized composition is stored at 5° C. for at least one month.

6. The composition of claim 4 , wherein the lyophilized composition is stored at −20° C. for at least one month.

7. The composition of claim 1 , wherein the nanoparticles have an average diameter of from 45 nm to 110 nm.

8. The composition of claim 1 , wherein the concentration of the nucleic acid active agents is from 1 mg/mL to 10 mg/mL.

9. The composition of claim 1 , wherein the lipid nanoparticles comprise a compound selected from compound A6, compound A9, compound AA, compound AB, compound C2, compound F5, compound F7, compound C24, and HEDC.

10. The composition of claim 1 , wherein the one or more nucleic acid active agents are RNAi molecules capable of mediating RNA interference.

11. The composition of claim 10 , wherein the RNAi molecules are siRNAs, shRNAs, ddRNAs, piRNAs, or rasiRNAs.

12. The composition of claim 1 , wherein the one or more nucleic acid active agents are miRNAs, antisense RNAs, plasmids, hybrid oligonucleotides, or aptamers.

13. The composition of claim 1 , wherein the pharmaceutically acceptable solution is a HEPES buffer, a phosphate buffer, a citrate buffer, or a buffer containing Tris(hydroxymethyl)aminomethane.

14. The composition of claim 1 , wherein the dextrin compound is a cyclodextrin.

15. The composition of claim 14 , wherein the cyclodextrin compound has one or more of the 2, 3 and 6 hydroxyl positions substituted with sulfoalkyl, benzenesulfoalkyl, acetoalkyl, hydroxyalkyl, hydroxyalkyl succinate, hydroxyalkyl malonate, hydroxyalkyl glutarate, hydroxyalkyl adipate, hydroxyalkyl, hydroxyalkyl maleate, hydroxyalkyl oxalate, hydroxyalkyl fumarate, hydroxyalkyl citrate, hydroxyalkyl tartrate, hydroxyalkyl malate, or hydroxyalkyl citraconate groups.

16. The composition of claim 14 , wherein the cyclodextrin compound is (2-hydroxypropyl)-β-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin succinate, (2-hydroxypropyl)-γ-cyclodextrin, or 2-hydroxypropyl-γ-cyclodextrin succinate.

17. The composition of claim 14 , wherein the cyclodextrin compound is sulfobutyl ether β-cyclodextrin or sulfobutyl ether γ-cyclodextrin.

18. The composition of claim 14 , wherein the cyclodextrin compound is methyl-β-cyclodextrin or methyl-γ-cyclodextrin.

19. The composition of claim 14 , wherein the cyclodextrin compound is attached to a polymer chain or network.

20. The composition of claim 14 , wherein the cyclodextrin compound includes an adsorbate compound.

21. The composition of claim 20 , wherein the adsorbate compound is selected from cholesterol, lanosterol, zymosterol, zymostenol, desmosterol, stigmastanol, dihydrolanosterol, 7-dehydrocholesterol, pegylated cholesterol, cholesteryl acetate, cholesteryl arachidonate, cholesteryl butyrate, cholesteryl hexanoate, cholesteryl myristate, cholesteryl palmitate, cholesteryl behenate, cholesteryl stearate, cholesteryl caprylate, cholesteryl n-decanoate, cholesteryl dodecanoate, cholesteryl nervonate, cholesteryl pelargonate, cholesteryl n-valerate, cholesteryl oleate, cholesteryl elaidate, cholesteryl erucate, cholesteryl heptanoate, cholesteryl linolelaidate, cholesteryl linoleate, beta-sitosterol, campesterol, ergosterol, brassicasterol, delta-7-stigmasterol, and delta-7-avenasterol.

22. The composition of claim 1 , wherein the saccharide sugar compound is a monosaccharide or disaccharide sugar compound.

23. The composition of claim 22 , wherein the sugar compound is selected from sucrose, lactose, lactulose, maltose, trehalose, cellobiose, kojibiose, sakebiose, isomaltose, sophorose, laminaribiose, gentiobiose, turanose, maltulose, isomaltulose, gentiobiulose, mannobiose, melibiose, melibiulose, and xylobiose.

24. A process for making a solid lyophile of one or more nucleic acid active agents, the process comprising lyophilizing a composition according to claim 1 .

25. A solid lyophile made by the process of claim 24 .

26. A process for making a drug product comprising reconstituting a solid lyophile according to claim 24 .

27. A drug product made by the process of claim 26 .

28. The composition of claim 1 , wherein upon lyophilization and reconstitution of the composition without filtering, the composition has less 0.001% (w/v) of aggregate particles with a size greater than 0.2 μm.

29. The composition of claim 1 , wherein upon lyophilization and reconstitution of the composition after a storage time period of six months, the composition retains at least 80% activity of the nucleic acid agents.

Assignees

• Nitto Denko Corp

Inventors

• Adami Roger
• Wang Yuwei
• Yin Haiqing
• Wang Liping
• Liu Dong
• Ying Wenbin

Classifications

• C12N2310/14

  interfering nucleic acids [NA] · CPC title

• A61K9/145

  with organic compounds · CPC title

• C12N2320/32

  Special delivery means, e.g. tissue-specific · CPC title

• C12N15/113

  Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title

• A61K9/19 Primary

  lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)} · CPC title